Racial Differences in the Use of Adjuvant Chemotherapy for Breast Cancer in a Large Urban Integrated Health System
Table 3
Logistic regression analysis of predictors of the receipt of adjuvant chemotherapy.
Unadjusted OR (95% C.I.)
Clinical factors OR* (95% C.I.)
Societal factors OR* (95% C.I.)
Adjusted OR* (95% C.I.)
African American
1.22 (1.02–1.46)
0.88 (0.67–1.14)
1.60 (1.26–2.04)
1.01 (0.72–1.42)
Age at diagnosisa
0.92 (0.91–0.93)
0.91 (0.90–0.92)
0.92 (0.91–0.94)
Large tumorb
4.66 (3.85–5.63)
3.71 (2.81–4.89)
3.76 (2.84–4.98)
Lymph node positive
8.99 (7.24–11.16)
10.18 (7.54–13.74)
10.28 (7.58–13.94)
ER−/PR−
3.68 (2.97–4.56)
3.49 (2.57–4.74)
3.56 (2.61–4.85)
Moderate/High grade
3.37 (2.63–4.32)
1.40 (1.00–1.98)
1.44 (1.02–2.04)
CCIc
0.68 (0.61–0.76)
0.93 (0.79–1.10)
0.95 (0.81–1.13)
Deprivation indexd
0.95 (0.89–1.01)
0.91 (0.84–0.99)
0.95 (0.85–1.07)
Medicaree
0.18 (0.15–0.22)
0.18 (0.15–0.22)
0.48 (0.34–0.68)
Other insurancee
0.66 (0.43–1.03)
0.68 (0.44–1.07)
0.43 (0.22–0.85)
adjusted for all listed variables.
aContinuous variable.
b≤2 cm is the referent.
cCharlson comorbidity index; continuous variable capped at 3.
dQuintiles, the least deprived area (quintile 1) is the referent.
ePrivate insurance is the referent.